CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Phase 2 Completed 82 enrolled Vaishali Sanchorawala Celgene Corporation · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs such as CC-5013 and dexamethasone may be effective in treating primary systemic amyloidosis. PURPOSE: This phase II trial is studying CC-5013 to see how well it works with or without dexamethasone in treating patients with primary systemic amyloidosis.

Timeline

Start: 2004-01
Primary completion: 2012-07
Completion: 2015-05

Publications

Lichtman EI, Seldin DC, Shelton A, Sanchorawala V. Single agent lenalidomide three times a week induces hematologic responses in AL amyloidosis patients on dialysis. Am J Hematol. 2014 Jul;89(7):706-8. doi: 10.1002/ajh.23722. Epub 2014 Apr 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dexamethasone	Small molecule	10 mg	Oral
Subject	Lenalidomide	Other / unclassified	15 mg	Oral

CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Summary

Timeline

Publications

Drugs

Indications